Medical specialists from Austria tagged as investigators in clinical trials studying Lymphoproliferative Disorders

Total 8 results

Alexandra Gruber-Wackernagel, MD
Seen in:
- Graz, Medical University of Graz, Department of Dermatology
- Styria, Graz, Medical University of Graz, Department of Dermatology
Trials:
- NCT03340155 (Sub-Investigator)
- NCT00638469 (Sub-Investigator)
Conditions:
- Lymphoproliferative Disorders;
- Psoriasis;
- Eczema;
- Pruritus;
- Vitiligo;
- Cutaneous T Cell Lymphoma;
- Mastocytosis;
- Graft Vs Host Disease;
- Lichen Planus;
- Prurigo;
- Polymorphic Light Eruption
Angelika Hofer, MD
Seen in:
- Graz, Medical University of Graz, Department of Dermatology
- Styria, Graz, Department of Dermatology, Medical University of Graz
- Styria, Graz, Medical University of Graz, Department of Dermatology
Trials:
- NCT04954573 (Sub-Investigator)
- NCT03340155 (Sub-Investigator)
- NCT00638469 (Sub-Investigator)
Conditions:
Franz Legat, MD
Seen in:
- Graz, Medical University of Graz, Department of Dermatology
- Styria, Graz, Department of Dermatology, Medical University of Graz
- Styria, Graz, Medical University of Graz, Department of Dermatology
Trials:
- NCT04954573 (Sub-Investigator)
- NCT03340155 (Sub-Investigator)
- NCT00638469 (Sub-Investigator)
Conditions:
Isabella Bambach
Seen in:
- Styria, Graz, Medical University of Graz, Department of Dermatology
Trials:
- NCT03340155 (Sub-Investigator)
Conditions:
- Lymphoproliferative Disorders;
- Psoriasis;
- Eczema;
- Pruritus;
- Vitiligo;
- Cutaneous T Cell Lymphoma;
- Mastocytosis;
- Graft Vs Host Disease;
- Lichen Planus;
- Prurigo;
- Polymorphic Light Eruption
Pablo Vieyra-Garcia, PhD
Seen in:
- Styria, Graz, Medical University of Graz, Department of Dermatology
Trials:
- NCT03340155 (Sub-Investigator)
Conditions:
- Lymphoproliferative Disorders;
- Psoriasis;
- Eczema;
- Pruritus;
- Vitiligo;
- Cutaneous T Cell Lymphoma;
- Mastocytosis;
- Graft Vs Host Disease;
- Lichen Planus;
- Prurigo;
- Polymorphic Light Eruption
Peter Wolf, MD
Seen in:
- Graz, Medical University of Graz, Department of Dermatology
- Styria, Graz, Medical University of Graz, Department of Dermatology
Trials:
- NCT03340155 (Principal Investigator)
- NCT00638469 (Principal Investigator)
Conditions:
- Lymphoproliferative Disorders;
- Psoriasis;
- Eczema;
- Pruritus;
- Vitiligo;
- Cutaneous T Cell Lymphoma;
- Mastocytosis;
- Graft Vs Host Disease;
- Lichen Planus;
- Prurigo;
- Polymorphic Light Eruption
Regina Fink-Puches, MD
Seen in:
- Styria, Graz, Medical University of Graz, Department of Dermatology
Trials:
- NCT03340155 (Sub-Investigator)
Conditions:
- Lymphoproliferative Disorders;
- Psoriasis;
- Eczema;
- Pruritus;
- Vitiligo;
- Cutaneous T Cell Lymphoma;
- Mastocytosis;
- Graft Vs Host Disease;
- Lichen Planus;
- Prurigo;
- Polymorphic Light Eruption
Wolfgang Weger, MD
Seen in:
- Graz, Medical University of Graz, Department of Dermatology
- Styria, Graz, Medical University of Graz, Department of Dermatology
Trials:
- NCT03340155 (Sub-Investigator)
- NCT00638469 (Sub-Investigator)
Conditions:
- Lymphoproliferative Disorders;
- Psoriasis;
- Eczema;
- Pruritus;
- Vitiligo;
- Cutaneous T Cell Lymphoma;
- Mastocytosis;
- Graft Vs Host Disease;
- Lichen Planus;
- Prurigo;
- Polymorphic Light Eruption

Clinical Trials on Lymphoproliferative Disorders

A.O. Ospedale Papa Giovanni XXIII

Completed

Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) (FCD-R)

Post-transplant Lymphoproliferative Disease (PTLD) | Non Burkitt

Italy
Becton, Dickinson and Company

Completed

Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel on the BD FACSLyric™ Flow Cytometer

Chronic Lymphoproliferative Diseases (CLPD)

United States, Switzerland, Spain, United Kingdom, Portugal
Geron Corporation

Completed

Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)

Chronic Lymphoproliferative Diseases

United States
Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH

Completed

Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy (PTLD-2)

Posttransplant Lymphoproliferative Disorder

Germany
Becton, Dickinson and Company

Completed

BD OneFlow CLPD Panel (BD OneFlow LST, and B-CLPD T1 to T4 Assays) on the BD FACSLyric System.

Chronic Lymphoproliferative Diseases (CLPD)

Portugal, United States, Spain, Switzerland
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Vaccine Therapy For Patients Being Considered For Organ Transplant Who Are at Risk For PTLD

Lymphoproliferative Disorder

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders

Recurrent Lymphoproliferative Disorder | Refractory Lymphoproliferative Disorder

United States
Charite University, Berlin, Germany

Terminated

Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)

Post-transplantation Lymphoproliferative Disorder

Australia, France, Germany, Sweden
Hospices Civils de Lyon

Completed

aCGH Impacts Survival in Plasma Cell PTLD

Post-transplantation Lymphoproliferative Disorders

France
Timothy Voorhees

Recruiting

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

Polymorphic Post-Transplant Lymphoproliferative Disorder | Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder

United States

Medical specialists from Austria tagged as investigators in clinical trials studying Lymphoproliferative Disorders

Clinical Trials on Lymphoproliferative Disorders

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations